Our results warrant further studies to determine whether hyperleptinemia associated with obesity contributes to mitochondrial-related cardiac pathology and whether this can be modified by therapeutic approaches aimed at attenuating the effects of leptin, such as the use of leptin receptor antagonists which may have therapeutic potential [49]. Here, LEPR is linked to obesity due to melanocortin 4 receptor deficiency.